Complementary function of the two catalytic domains of APOBEC3G

被引:268
作者
Navarro, F [1 ]
Bollman, B [1 ]
Chen, H [1 ]
König, R [1 ]
Yu, Q [1 ]
Chiles, K [1 ]
Landau, NR [1 ]
机构
[1] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA
关键词
APOBEC3G; Vif; HIV-1; encapsidation; deamination;
D O I
10.1016/j.virol.2005.01.011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The HIV-1 viral accessory protein Vif prevents the encapsidation of the antiviral cellular cytidine deaminases APOBEC3F and APOBEC3G by inducing their proteasomal degradation. In the absence of Vif, APOBEC3G is encapsidated and blocks virus replication by deaminating cytosines of the viral cDNA. APOBEC3G encapsidation has been recently shown to depend on the viral nucleocapsid protein; however, the role of RNA remains unclear. Using APOBEC3G deletion and point mutants, we mapped the encapsidation determinant to the Zn2+ coordination residues of the N-terminal catalytic domain (CD1). Notably, these residues were also required for RNA binding. Mutations in the two aromatic residues of CD1 but not CD2, which are conserved in cytidine deaminase core domains and are required for RNA binding, prevented encapsidation into HIV-1, HTLV-1 and MLV. The Zn2+ coordination residues of the C-terminal catalytic domain (CD2) were not required for encapsidation but were essential for cytidine deaminase activity and the antiviral effect. These findings suggest a model in which CD1 mediates encapsidation and RNA binding while CD2 mediates cytidine deaminase activity. Interestingly, HTLV-1 was relatively resistant to the antiviral effects of encapsidated APOBEC3G. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:374 / 386
页数:13
相关论文
共 48 条
[31]   Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor [J].
Schäfer, A ;
Bogerd, HP ;
Cullen, BR .
VIROLOGY, 2004, 328 (02) :163-168
[32]   A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif) [J].
Schröfelbauer, R ;
Chen, D ;
Landau, NR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (11) :3927-3932
[33]   The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif [J].
Sheehy, AM ;
Gaddis, NC ;
Malim, MH .
NATURE MEDICINE, 2003, 9 (11) :1404-1407
[34]   Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein [J].
Sheehy, AM ;
Gaddis, NC ;
Choi, JD ;
Malim, MH .
NATURE, 2002, 418 (6898) :646-650
[35]   The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity [J].
Shindo, K ;
Takaori-Kondo, A ;
Kobayashi, M ;
Abudu, A ;
Fukunaga, K ;
Uchiyama, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) :44412-44416
[36]   A TRANSIENT 3-PLASMID EXPRESSION SYSTEM FOR THE PRODUCTION OF HIGH-TITER RETROVIRAL VECTORS [J].
SONEOKA, Y ;
CANNON, PM ;
RAMSDALE, EE ;
GRIFFITHS, JC ;
ROMANO, G ;
KINGSMAN, SM ;
KINGSMAN, AJ .
NUCLEIC ACIDS RESEARCH, 1995, 23 (04) :628-633
[37]   HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability [J].
Stopak, K ;
de Noronha, C ;
Yonemoto, W ;
Greene, WC .
MOLECULAR CELL, 2003, 12 (03) :591-601
[38]   Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 Virions through interactions with viral and nonviral RNAs [J].
Svarovskaia, ES ;
Xu, HZ ;
Mbisa, JL ;
Barr, R ;
Gorelick, RJ ;
Ono, A ;
Freed, EO ;
Hu, WS ;
Pathak, VK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (34) :35822-35828
[39]   Inhibition of hepatitis B virus replication by APOBEC3G [J].
Turelli, P ;
Mangeat, B ;
Jost, S ;
Vianin, S ;
Trono, D .
SCIENCE, 2004, 303 (5665) :1829-1829
[40]   Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business [J].
Wedekind, JE ;
Dance, GSC ;
Sowden, MP ;
Smith, HC .
TRENDS IN GENETICS, 2003, 19 (04) :207-216